Navigate BioPharma Services, Inc. announces collaboration with RareCyte, Inc. to provide enhanced spatial biology capabilities using the Orion™ Platform.
Carlsbad, Calif. – April 9, 2024. Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications announces the launch of its new multiplex spatial biology assay services for rapid, whole-slide imaging and analysis of tissue sections at subcellular resolution. These assays utilize the Orion™ platform from RareCyte, Inc. and feature ready-to-run assay panels, as well as customization to serve studies across multiple drug targets and therapeutic areas.
This collaboration aims to leverage the complementary expertise of both companies to provide end-to-end spatial biology services for pharmaceutical and clinical institutions worldwide. The RareCyte Orion platform has been used to understand a range of diseases, to elucidate highly prognostic biomarkers for diagnosis and to study the mechanism of action of neoadjuvant immune therapies. Navigate provides years of experience in developing high-plex imaging assays and creating highly customized biomarker solutions for immuno-oncology and oncology clinical trials.